Compare Kinder Morgan Inc (KMI) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Novavax Inc — how do they compare? Kinder Morgan Inc trades at $32.54 (market cap $71.81B), while Novavax Inc trades at $12.98 (market cap $1.82B). The key difference: Kinder Morgan Inc is far larger — about 39.5× Novavax Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Novavax Inc for 59 Days on average.
| KMI | NVAX | |
|---|---|---|
Market Cap | $71.81B | $1.82B |
Volume | 16,921,908 | 6,198,505 |
Sector | Energy | Health |
52-Week High | $34.31 | $12.56 |
52-Week Low | $25.84 | $6.22 |
Typical Hold Time | 150 Days | 59 Days |
Enterprise Value | $103.86B | $1.39B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.36, up 1.7% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with revenue growth from $15.1B in 2024 to $16.9B in 2025 and consistent earnings beats, while maintaining a 19.31% net income margin. Recent news highlights the company's $6B-$7B growth pipeline and resilience in volatile energy markets.
KMI presents a compelling investment case with analyst consensus target of $37.20 (15% upside), strong dividend yield, and fee-based revenue model. Key risks include energy market volatility and high debt levels, but the company's project backlog and natural gas demand growth support positive long-term outlook.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
